<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>肿瘤资讯 | wechat-feeds</title><link>http://MjM5Nzc4MDk2MA.favicon.privacyhide.com/favicon.ico</link><description>分享肿瘤领域最新进展，传播正确肿瘤防治理念，提高全社会对肿瘤的关注！新浪微博：@肿瘤资讯</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 11 Apr 2021 21:27:58 +0800</pubDate><image><url>http://MjM5Nzc4MDk2MA.favicon.privacyhide.com/favicon.ico</url><title>肿瘤资讯 | wechat-feeds</title><link>http://MjM5Nzc4MDk2MA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>【2793】&#x9;ESMO-EURACAN指南 | 鼻咽癌诊断、治疗和随访</title><link>https://mp.weixin.qq.com/s/7Mrx1RTpVHy1UEQpgTXJxg</link><description></description><content:encoded><![CDATA[【2793】	ESMO-EURACAN指南 | 鼻咽癌诊断、治疗和随访]]></content:encoded><pubDate>Sun, 11 Apr 2021 19:54:22 +0800</pubDate></item><item><title>【Cancer Discover】TAK-788用于EGFR外显子20插入突变经治晚期NSCLC的疗效和安全性</title><link>https://mp.weixin.qq.com/s/wCsPpDfcCLXf3Leja-JoHg</link><description></description><content:encoded><![CDATA[【Cancer Discover】TAK-788用于EGFR外显子20插入突变经治晚期NSCLC的疗效和安全性]]></content:encoded><pubDate>Sun, 11 Apr 2021 19:54:22 +0800</pubDate></item><item><title>CheckMate -649中国亚组完整数据出炉！O药联合化疗一线治疗中国晚期胃癌患者证实生存获益</title><link>https://mp.weixin.qq.com/s/90u65srVQPJEoIFCMKpsJw</link><description></description><content:encoded><![CDATA[CheckMate -649中国亚组完整数据出炉！O药联合化疗一线治疗中国晚期胃癌患者证实生存获益]]></content:encoded><pubDate>Sun, 11 Apr 2021 19:54:22 +0800</pubDate></item><item><title>铂类药物晚期乳腺癌应用专家共识（2020版）</title><link>https://mp.weixin.qq.com/s/KnGlTMHEAyTqqno9qCMY0A</link><description></description><content:encoded><![CDATA[铂类药物晚期乳腺癌应用专家共识（2020版）]]></content:encoded><pubDate>Sun, 11 Apr 2021 19:54:22 +0800</pubDate></item><item><title>【2792】朱耀教授：口服GnRH拮抗剂Relugolix惊艳问世，HERO缔造前列腺癌新豪杰</title><link>https://mp.weixin.qq.com/s/POxXKNusmpUoFJWGGIvXnw</link><description></description><content:encoded><![CDATA[【2792】朱耀教授：口服GnRH拮抗剂Relugolix惊艳问世，HERO缔造前列腺癌新豪杰]]></content:encoded><pubDate>Sat, 10 Apr 2021 19:05:48 +0800</pubDate></item><item><title>与君共赏，详细解读最新版CSCO BC诊疗指南，2021 全国乳腺癌大会精彩内容倾情奉上</title><link>https://mp.weixin.qq.com/s/bexdKo2U_qkLjXOSURBAHQ</link><description></description><content:encoded><![CDATA[与君共赏，详细解读最新版CSCO BC诊疗指南，2021 全国乳腺癌大会精彩内容倾情奉上]]></content:encoded><pubDate>Sat, 10 Apr 2021 19:05:48 +0800</pubDate></item><item><title>【中国好声音】沈琳教授&amp;张艳桥教授团队：卡瑞利珠单抗+化疗序贯卡瑞利珠+阿帕替尼一线治疗晚期胃腺癌曙光初现</title><link>https://mp.weixin.qq.com/s/v91K6kR7S-Jp4qCKXgc-dw</link><description></description><content:encoded><![CDATA[【中国好声音】沈琳教授&张艳桥教授团队：卡瑞利珠单抗+化疗序贯卡瑞利珠+阿帕替尼一线治疗晚期胃腺癌曙光初现]]></content:encoded><pubDate>Sat, 10 Apr 2021 19:05:48 +0800</pubDate></item><item><title>【JNCCN】多中心回顾性研究：CDK4/6抑制剂哌柏西利进展后使用阿贝西利治疗，PFS和OS均有获益</title><link>https://mp.weixin.qq.com/s/cIgVCJb-T6noooZCG28GLA</link><description></description><content:encoded><![CDATA[【JNCCN】多中心回顾性研究：CDK4/6抑制剂哌柏西利进展后使用阿贝西利治疗，PFS和OS均有获益]]></content:encoded><pubDate>Sat, 10 Apr 2021 19:05:48 +0800</pubDate></item><item><title>【2791】秦叔逵教授：凭借东风上青云，RC48-ADC彰显民族制药新高度</title><link>https://mp.weixin.qq.com/s/ovQBZjdbU1pIXRxzK6dZHA</link><description></description><content:encoded><![CDATA[【2791】秦叔逵教授：凭借东风上青云，RC48-ADC彰显民族制药新高度]]></content:encoded><pubDate>Fri, 09 Apr 2021 19:38:36 +0800</pubDate></item><item><title>应建明教授：国内首个RET抑制剂普拉替尼获批，规范化RET融合基因检测势在必行</title><link>https://mp.weixin.qq.com/s/55hvmibNEv0l-dhsSAmpag</link><description></description><content:encoded><![CDATA[应建明教授：国内首个RET抑制剂普拉替尼获批，规范化RET融合基因检测势在必行]]></content:encoded><pubDate>Fri, 09 Apr 2021 19:38:36 +0800</pubDate></item><item><title>吴一龙教授、钟文昭教授肺癌MDT中国专家共识解读</title><link>https://mp.weixin.qq.com/s/fKMCfEgPN7GWnHST9L_F6g</link><description></description><content:encoded><![CDATA[吴一龙教授、钟文昭教授肺癌MDT中国专家共识解读]]></content:encoded><pubDate>Fri, 09 Apr 2021 19:38:36 +0800</pubDate></item><item><title>【AACR 2021】临床试验迷你座谈会上的中国好声音</title><link>https://mp.weixin.qq.com/s/Pok5TVXVTWI8NQs24itoQQ</link><description></description><content:encoded><![CDATA[【AACR 2021】临床试验迷你座谈会上的中国好声音]]></content:encoded><pubDate>Fri, 09 Apr 2021 19:38:36 +0800</pubDate></item><item><title>【TOP TALK】百“肺”待新：中外专家共话肺癌免疫新辅助治疗</title><link>https://mp.weixin.qq.com/s/aw_006yHeZcCRijePfyPrw</link><description></description><content:encoded><![CDATA[【TOP TALK】百“肺”待新：中外专家共话肺癌免疫新辅助治疗]]></content:encoded><pubDate>Fri, 09 Apr 2021 19:38:36 +0800</pubDate></item><item><title>捷报频传！瑞派替尼获批上市，AACR将再添喜讯！晚期GIST迎福音</title><link>https://mp.weixin.qq.com/s/4KJVfjuvjEZJaXEsUmd9uw</link><description></description><content:encoded><![CDATA[捷报频传！瑞派替尼获批上市，AACR将再添喜讯！晚期GIST迎福音]]></content:encoded><pubDate>Fri, 09 Apr 2021 19:38:36 +0800</pubDate></item><item><title>【CDK4/6i学院】RWS佐证OS获益重磅出道，王树森教授：哌柏西利+LET一线治疗显著改善降低HR+mBC患者死亡风险42%</title><link>https://mp.weixin.qq.com/s/udxmu3Znb3_AbhxVTl66Sg</link><description></description><content:encoded><![CDATA[【CDK4/6i学院】RWS佐证OS获益重磅出道，王树森教授：哌柏西利+LET一线治疗显著改善降低HR+mBC患者死亡风险42%]]></content:encoded><pubDate>Fri, 09 Apr 2021 19:38:36 +0800</pubDate></item><item><title>中医肿瘤的病机——痰湿凝聚</title><link>https://mp.weixin.qq.com/s/Oe_nMmJoZw3XaAwwaJLQFw</link><description></description><content:encoded><![CDATA[中医肿瘤的病机——痰湿凝聚]]></content:encoded><pubDate>Fri, 09 Apr 2021 19:38:36 +0800</pubDate></item><item><title>【2790】叶颖江教授：阿伐替尼中国获批丨开启GIST基因驱动治疗新时代</title><link>https://mp.weixin.qq.com/s/9WhIvTkPSNX0RN1FZJ2T5w</link><description></description><content:encoded><![CDATA[【2790】叶颖江教授：阿伐替尼中国获批丨开启GIST基因驱动治疗新时代]]></content:encoded><pubDate>Thu, 08 Apr 2021 19:54:43 +0800</pubDate></item><item><title>ASCO/OH(CCO)联合指南更新：携带驱动基因改变Ⅳ期非小细胞肺癌的治疗</title><link>https://mp.weixin.qq.com/s/UY_35G20ODkpk0eH_7euOg</link><description></description><content:encoded><![CDATA[ASCO/OH(CCO)联合指南更新：携带驱动基因改变Ⅳ期非小细胞肺癌的治疗]]></content:encoded><pubDate>Thu, 08 Apr 2021 19:54:43 +0800</pubDate></item><item><title>【晚美新生大咖谈】王晓稼教授：以实力说话， CDK4/6抑制剂正书写HR+晚期乳腺癌靶向时代新篇章</title><link>https://mp.weixin.qq.com/s/-jri5yGTgdM-_VRJ7hS50w</link><description></description><content:encoded><![CDATA[【晚美新生大咖谈】王晓稼教授：以实力说话， CDK4/6抑制剂正书写HR+晚期乳腺癌靶向时代新篇章]]></content:encoded><pubDate>Thu, 08 Apr 2021 19:54:43 +0800</pubDate></item><item><title>一图读懂：普拉替尼（普吉华®）中国首个RET抑制剂获批！</title><link>https://mp.weixin.qq.com/s/WLKW0fcc2Ejwv929bCP_xA</link><description></description><content:encoded><![CDATA[一图读懂：普拉替尼（普吉华®）中国首个RET抑制剂获批！]]></content:encoded><pubDate>Thu, 08 Apr 2021 19:54:43 +0800</pubDate></item></channel></rss>